Skip to main content
FBLG
NASDAQ Life Sciences

$3M Direct Offering Bolsters FibroBiologics, Clinical Trial Patient Dosing Expected Q2

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.346
Mkt Cap
$4.637M
52W Low
$1.03
52W High
$22.6
52W Position info
31% above low
Off High info
94% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

FBLG sits 31% above its 52-week low of $1.03 on light trading volume (0.1× avg).

Summary

FibroBiologics reported its Q1 2026 financial results, which included a net loss of $5.0 million (previously reported). Crucially, the company announced it raised $3 million through a direct offering, a significant capital infusion for a company with a market capitalization of approximately $4.6 million. This financing provides critical runway for its operations. Additionally, FibroBiologics provided a comprehensive corporate update, highlighting significant progress in its clinical pipeline, including being on track to dose the first patient in its Phase 1/2 clinical trial for diabetic foot ulcers (CYWC628) in Q2 2026. The company also reported positive preclinical results for its burn and degenerative disc disease programs and outlined upcoming milestones, such as IND clearance for psoriasis in Q3 2026 and IND submission for multiple sclerosis in H2 2026. This update provides material new information regarding financing and clinical development, which are key value drivers for a clinical-stage biotechnology company. Investors will be watching for the first patient dosing and subsequent clinical data readouts.

At the time of this announcement, FBLG was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $1.03 to $22.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

FBLG - Latest Insights

FBLG
Oct 08, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.13
Real-time Price: $0.900 info
Change: -$0.230 (-20%) info
Market Cap: $6.152M info
FBLG
Sep 18, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.43
Real-time Price: $0.900 info
Change: -$0.530 (-37%) info
Market Cap: $6.152M info
FBLG
Sep 17, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.49
Real-time Price: $0.900 info
Change: -$0.585 (-39%) info
Market Cap: $6.152M info
FBLG
Sep 15, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $0.900 info
Change: -$0.6479 (-42%) info
Market Cap: $6.152M info
FBLG
Aug 11, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.950
Real-time Price: $0.900 info
Change: -$0.050 (-5%) info
Market Cap: $6.152M info